Follistatin 344 vs MK-677

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Follistatin-344 is the predominant endogenous isoform of follistatin, a glycoprotein that binds and neutralizes the TGF-β superfamily members activin A and myostatin, preventing their engagement with skeletal muscle ActRII receptors and thereby relieving their inhibitory effects on muscle protein synthesis and satellite cell activation. By sequestering both myostatin and activin A simultaneously, follistatin-344 neutralizes two complementary negative regulators of muscle growth through a dual-pathway mechanism, a property that distinguishes it from agents that target only the myostatin pathway. Transgenic expression of human follistatin-344 has produced significant skeletal muscle mass increases in animal models, and a phase 1/2a gene therapy trial delivering the follistatin-344 gene via AAV to patients with Becker muscular dystrophy established initial proof of concept and safety data in a human clinical context. Follistatin-344 has not received FDA approval for any indication; exogenous administration as a recombinant protein or peptide is investigational and no human safety data exists for this route of administration outside gene therapy trial contexts. Follistatin-344 as a research compound: recombinant follistatin-344 protein is available through research biochemical suppliers as a laboratory reagent, used in cell culture and animal models to probe myostatin and activin A biology. Interest in exogenous follistatin-344 administration in performance contexts has grown from the animal model hypertrophy data; however, the protein's large molecular weight (~35 kDa glycoprotein) creates significant bioavailability challenges for subcutaneous or intramuscular routes, and no human pharmacokinetic data supports assumed tissue distribution from injection. This distinguishes it from smaller peptide-based myostatin modulators. Follistatin-344 vs myostatin propeptide: both target myostatin inhibition but through different binding mechanisms. Follistatin-344 binds activin A in addition to myostatin, providing a broader TGF-β inhibition profile. Myostatin propeptide is the endogenous inhibitory domain of the myostatin precursor protein — it is myostatin-specific but structurally derived from the same protein rather than from a binding antagonist class. Both compounds remain at the research stage for performance applications with no approved human use. Providers offering research peptides in the performance and muscle recovery category are listed in the PeptideBase directory.

MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.

MK-677 (ibutamoren; ibutamoren mesylate) is an orally active, non-peptide small-molecule ghrelin receptor (GHS-R1a) agonist developed by Merck as a research compound for GH deficiency and muscle-wasting conditions, notable as one of the few GH secretagogues with confirmed oral bioavailability and a substantial human clinical dataset spanning multiple Phase 2 randomized controlled trials. MK-677 mimics ghrelin to stimulate pulsatile GH and IGF-1 secretion from the pituitary in a dose-dependent manner without directly replacing GH, and RCTs have demonstrated significant increases in fat-free mass and GH secretion in obese adults and in hemodialysis patients with nutritional deficits, establishing the pharmacology of oral GHS-R1a agonism in humans. Despite robust human pharmacological evidence, MK-677 was not advanced to FDA registration; Merck Phase 3 trials showed efficacy on surrogate endpoints but did not demonstrate the clinical outcomes required for approval, commercial development was discontinued, and no approved indication exists. MK-677 is a non-peptide research compound — not a peptide in the pharmacological sense — with no FDA approval; it is widely available through research chemical suppliers and used off-label, and considerations including its documented effects on insulin sensitivity, fasting glucose, and sustained IGF-1 elevation are relevant to its risk profile. MK-677 dosage: clinical trials studied doses of 10 mg, 25 mg, and 50 mg orally once daily. The most frequently cited research dose in the literature is 25 mg/day for body composition studies; 10 mg/day has been used in elderly populations. Administration before sleep is studied to align the GH pulse with the natural nocturnal GH peak. Unlike injectable GH secretagogues that require reconstitution, MK-677's oral route is a practical distinction — it eliminates the injection preparation process relevant to peptides requiring bacteriostatic water reconstitution. Side effects documented in RCTs include increased appetite (a direct ghrelin-mimetic effect), mild peripheral edema from water retention, and transient increases in fasting blood glucose — a clinically relevant finding for individuals with pre-existing insulin sensitivity concerns. Sustained IGF-1 elevation from long-duration use is a differentiated risk characteristic compared to short-half-life injectable GHRPs. MK-677 is sometimes grouped with performance peptides due to overlapping research contexts but is pharmacologically a non-peptide small molecule. Licensed telehealth and anti-aging providers who carry growth hormone secretagogues are listed in the PeptideBase directory.